Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of ProPhase Labs Inc (NASDAQ: PRPH) was $0.57 for the day, up 29.84% from the previous closing price of $0.44. In other words, the price has increased by $29.84 from its previous closing price. On the day, 60.75 million shares were traded.
Ratios:
Our analysis of PRPH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.33 and its Current Ratio is at 1.47. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 20, 2021, initiated with a Buy rating and assigned the stock a target price of $12.
On January 20, 2021, Dawson James started tracking the stock assigning a Buy rating and target price of $25.Dawson James initiated its Buy rating on January 20, 2021, with a $25 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.34 while its Price-to-Book (P/B) ratio in mrq is 0.29.
Stock Price History:
Over the past 52 weeks, PRPH has reached a high of $7.48, while it has fallen to a 52-week low of $0.22. The 50-Day Moving Average of the stock is 3.66%, while the 200-Day Moving Average is calculated to be -76.26%.
Shares Statistics:
A total of 29.87M shares are outstanding, with a floating share count of 25.70M. Insiders hold about 13.96% of the company’s shares, while institutions hold 8.10% stake in the company.
Earnings Estimates
The market rating of ProPhase Labs Inc (PRPH) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.18 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$1.27 and -$1.27 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$0.56, with 1.0 analysts recommending between -$0.56 and -$0.56.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $3.77M to a low estimate of $3.77M. As of the current estimate, ProPhase Labs Inc’s year-ago sales were $4.35MFor the next quarter, 1 analysts are estimating revenue of $2.45M. There is a high estimate of $2.45M for the next quarter, whereas the lowest estimate is $2.45M.
A total of 1 analysts have provided revenue estimates for PRPH’s current fiscal year. The highest revenue estimate was $13.02M, while the lowest revenue estimate was $13.02M, resulting in an average revenue estimate of $13.02M. In the same quarter a year ago, actual revenue was $45.24MBased on 1 analysts’ estimates, the company’s revenue will be $21.36M in the next fiscal year. The high estimate is $21.36M and the low estimate is $21.36M.
